Brookfield Asset Management Inc. Neurocrine Biosciences Inc Transaction History
Brookfield Asset Management Inc.
- $14 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
626Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.94 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.36 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$703 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$351 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$254 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...